These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31416790)

  • 1. Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity.
    Lee C; Choi SK; Kim RK; Kim H; Whang YH; Pharm H; Cheon H; Yoon DY; Kim CW; Baik YO; Park SS; Lee I
    Biologicals; 2019 Sep; 61():32-37. PubMed ID: 31416790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants.
    Xie J; Zhang Y; Caro-Aguilar I; Indrawati L; Smith WJ; Giovarelli C; Winters MA; MacNair J; He J; Abeygunawardana C; Musey L; Kosinski M; Skinner JM
    Pediatr Infect Dis J; 2020 Jan; 39(1):70-77. PubMed ID: 31725555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
    Rupp R; Hurley D; Grayson S; Li J; Nolan K; McFetridge RD; Hartzel J; Abeygunawardana C; Winters M; Pujar H; Benner P; Musey L
    Hum Vaccin Immunother; 2019; 15(3):549-559. PubMed ID: 30689507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
    Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
    Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
    Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.
    Sobanjo-ter Meulen A; Vesikari T; Malacaman EA; Shapiro SA; Dallas MJ; Hoover PA; McFetridge R; Stek JE; Marchese RD; Hartzel J; Watson WJ; Musey LK
    Pediatr Infect Dis J; 2015 Feb; 34(2):186-94. PubMed ID: 25741971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age.
    Kanevsky I; Surendran N; McElwee K; Lei L; Watson W; Pride M; Scully I; Karauzum H; Anderson A; Young M
    Vaccine; 2023 Oct; 41(45):6625-6629. PubMed ID: 37793976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
    Ermlich SJ; Andrews CP; Folkerth S; Rupp R; Greenberg D; McFetridge RD; Hartzel J; Marchese RD; Stek JE; Abeygunawardana C; Musey LK
    Vaccine; 2018 Oct; 36(45):6875-6882. PubMed ID: 29559167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
    Greenberg D; Hoover PA; Vesikari T; Peltier C; Hurley DC; McFetridge RD; Dallas M; Hartzel J; Marchese RD; Coller BG; Stek JE; Abeygunawardana C; Winters MA; MacNair JE; Pujar NS; Musey L
    Vaccine; 2018 Oct; 36(45):6883-6891. PubMed ID: 30244873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model.
    Park C; Kwon EY; Choi SM; Cho SY; Byun JH; Park JY; Lee DG; Kang JH; Shin J; Kim H
    Hum Vaccin Immunother; 2017 May; 13(5):1169-1176. PubMed ID: 27960627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.
    Caro-Aguilar I; Indrawati L; Kaufhold RM; Gaunt C; Zhang Y; Nawrocki DK; Giovarelli C; Winters MA; Smith WJ; Heinrichs J; Skinner JM
    Vaccine; 2017 Feb; 35(6):865-872. PubMed ID: 28087148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of aluminum adjuvants on the stability of pneumococcal polysaccharide-protein conjugate vaccines.
    Smith WJ; Thompson R; Egan PM; Zhang Y; Indrawati L; Skinner JM; Blue JT; Winters MA
    Vaccine; 2023 Aug; 41(35):5113-5125. PubMed ID: 37321893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice.
    McGuinness D; Kaufhold RM; McHugh PM; Winters MA; Smith WJ; Giovarelli C; He J; Zhang Y; Musey L; Skinner JM
    Vaccine; 2021 Jul; 39(30):4231-4237. PubMed ID: 34074546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides.
    Tan CY; Immermann FW; Sebastian S; Pride MW; Pavliakova D; Belanger KA; Watson W; Scott DA; Sidhu M; Jansen KU; Giardina PC
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30089644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.